Adjuvant Pembrolizumab in Patients with Stage IIIA/N2 Non-Small Cell Lung Cancer Completely Resected after Neoadjuvant Concurrent Chemoradiation: A Prospective, Open-Label, Single-Arm, Phase 2 Trial.

Cancer Res Treat · 2024 · PMC11491244 · PMID 38697848

Europe PMC DOI

hedged sentence

0.3340

closest p · 6.7× alpha

0.3340

boldest claim

The sentences

did not reach statistical significancep=0.334not close (p > 0.1)

There was a trend toward improved DFS in patients without EGFR/ALK alterations, although it did not reach statistical significance (HR for patients with vs. without EGFR/ALK alterations, 1.47; 95% CI, 0.67 to 3.19; p=0.334).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.